Comments on ICER’s Type 2 Diabetes Report

Several methodological issues in the draft evidence report for oral semaglutide are likely biasing the results toward an overly restrictive cost-effectiveness result. These issues include:

  • Not adequately accounting for the additional patient benefits that a once-daily oral formulation provides
  • Not adequately accounting for the co-morbidities associated with Type 2 diabetes
  • Underestimating the full costs Type 2 diabetes impose on patients and their caregivers
  • Not adequately accounting for the well-documented heterogeneity across Type 2 diabetes patients.

Read the Comments

Categorized in: